Abstract: Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.
Abstract: Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.
Abstract: Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.
Abstract: Disclosed are a novel Bifidobacterium longum RAPO (Accession No.: KCTC 13773BP) and a composition for alleviating, treating or preventing rheumatoid arthritis containing Bifidobacterium longum RAPO (Accession No.: KCTC 13773BP) selected herein.
Type:
Grant
Filed:
October 15, 2019
Date of Patent:
October 5, 2021
Assignees:
THE CATHOLIC UNIVERSITY OF KOREA, BIFIDO CO., LTD.
Inventors:
Geun Eog Ji, Yun Ju Jeong, Sang Jun Park, Su Young Yang, Hyon Ha Lee, Sung Hwan Park, Mi La Cho, Ji Hyeon Ju, Seung Ki Kwok, Joo Ha Lee, Ji Won Kim, Seon Yeong Lee, Jun Geol Ryu, Joo Yeon Jhun, Jae Yoon Ryu
Abstract: Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.
Abstract: Provided is a prebiotic composition containing butyryl-fructooligosaccharide (B-FOS). B-FOS of the present invention facilitates selective growth of probiotics, thereby controlling intestinal microbes and contributing to physiological functions as an energy source of intestinal epithelial cells.
Type:
Grant
Filed:
June 29, 2018
Date of Patent:
August 24, 2021
Assignee:
BIFIDO CO., LTD.
Inventors:
Geun Eog Ji, Min Hee Um, Si Ni Kang, Myeong Soo Park, Bin Kwon
Abstract: Provided is a composition containing Bifidobacterium for alleviating, preventing or treating rheumatoid arthritis. The Bifidobacterium bifidum ATT newly isolated according to the present invention is useful as a rheumatoid arthritis medicine or a probiotic material for alleviating rheumatoid arthritis owing to potent efficacy in treating rheumatoid arthritis.
Type:
Grant
Filed:
May 11, 2018
Date of Patent:
April 14, 2020
Assignees:
BIFIDO CO., LTD., THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Geun Eog Ji, Yunju Jeong, Hui Fang, Bin Kwon, Sung-Hwan Park, Mi-La Cho, Ji-Hyeon Ju, Seung-Ki Kwok, Jennifer Lee, Ji-Won Kim, Seon-Yeong Lee, Jun-Geol Ryu, Joo-Yeon Jhun, Jae-yoon Ryu, Hyeon-Beom Seo
Abstract: Provided is a prebiotic composition containing butyryl-fructooligosaccharide (B-FOS). B-FOS of the present invention facilitates selective growth of probiotics, thereby controlling intestinal microbes and contributing to physiological functions as an energy source of intestinal epithelial cells.
Type:
Application
Filed:
June 29, 2018
Publication date:
November 14, 2019
Applicant:
BIFIDO CO., LTD.
Inventors:
Geun Eog JI, Min Hee UM, Si Ni KANG, Myeong Soo PARK, Bin KWON
Abstract: Provided is a composition containing Bifidobacterium for alleviating, preventing or treating rheumatoid arthritis. The Bifidobacterium bifidum ATT newly isolated according to the present invention is useful as a rheumatoid arthritis medicine or a probiotic material for alleviating rheumatoid arthritis owing to potent efficacy in treating rheumatoid arthritis.
Type:
Application
Filed:
May 11, 2018
Publication date:
August 1, 2019
Applicants:
BIFIDO CO., LTD., THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Geun Eog JI, Yunju JEONG, Hui FANG, KWON, Bin KWON, Bin, Sung-Hwan PARK, Mi-La CHO, Ji-Hyeon JU, Seung-Ki KWOK, Jennifer LEE, Ji-Won KIM, Seon-Yeong LEE, Jun-Geol RYU, Joo-Yeon JHUN, Jae-yoon RYU, Hyeon-Beom SEO
Abstract: The present invention relates to a new plasmid originated from (Bifidobacterium) a recombinant expression vector and transformation method using the same. More particularly, the present invention relates to a plasmid pMG1 having nucleotide sequence represented by SEQ.ID.NO.1; (Bifidobacterium longum) MG1 including the plasmid pMG1; and a shuttle vector which can be replicated in both (Bifidobacterium) and (E. coli), and comprises (Mob) gene having nucleotide sequence represented by SEQ.ID.NO.2. (Rep) gene having nucleotide sequence represented by SEQ.ID.NO.3 and a selection marker. The shuttle vector and the promoter of the present invention can be used for expressing target gene without additional purification process.
Type:
Grant
Filed:
March 30, 2001
Date of Patent:
May 3, 2005
Assignee:
Bifido Co., Ltd.
Inventors:
Geun-Eog Ji, Myeong-Soo Park, Yun-Hee Kang, Jung-Min Seo